Skip to main content
. Author manuscript; available in PMC: 2017 Sep 1.
Published in final edited form as: Eur J Cancer. 2016 Jun 30;64:89–95. doi: 10.1016/j.ejca.2016.05.009

Table 1.

Patient characteristics (N=216)

Characteristics N (%)*
Age, average (range) 54.9 (22 – 79)
Sex
 Female 126 (58)
 Male 90 (42)
Ethnicity
 White 143 (66)
 Black 43 (20)
 Hispanic 28 (13)
 Others 2 (1)
Education
 High school or lower 115 (53)
 College 72 (33)
 Advanced 29 (14)
Cancer
 Breast 27 (13)
 Gastrointestinal 71 (33)
 Genitourinary 19 (9)
 Gynecological 23 (11)
 Head and neck 10 (5)
 Hematological 12 (6)
 Others 18 (8)
 Respiratory 36 (17)
Overall survival in days, median (95% confidence interval) 109 (71–133)
Clinician prediction of survival (Raw-CPS) in days, median (interquartile range) 90 (60–155)
Palliative prognostic score (PaP-total score)
 0–5.5 points 152 (70)
 5.6–11 points 16 (8)
 11.1–17.5 points 48 (22)
Clinician prediction of survival transformed into PaP score categories (PaP-CPS)
 >12 weeks (0 point) 128 (59)
 11–12 weeks (2 points) 3 (1)
 7–10 weeks (2.5 points) 48 (22)
 5–6 weeks (4.5 points) 11 (5)
 3–4 weeks (6 points) 23 (11)
 <=2 weeks (8.5 points) 3 (1)
Dyspnea in PaP score categories
 Absent (0 point) 125 (58)
 Present (1 point) 91 (42)
Anorexia in PaP score categories
 Absent (0 point) 187 (87)
 Present (1.5 points) 29 (13)
Karnofsky performance status in PaP score categories
 ≥50% (0 point) 182 (84)
 ≤40% (2.5 points) 34 (16)
Leukocytosis in PaP score categories
 ≤8500 cell/mm3 (0 point) 130 (60)
 8501–11000 cell/mm3 (0.5 point) 42 (20)
 >11000 cell/mm3 (1.5 points) 44 (20)
Lymphocytopenia in PaP score categories
 ≥20% (0 point) 42 (20)
 12%-19.9% (1 point) 46 (21)
 0–11.9% (2.5 points) 128 (59)

Abbreviations: SD, standard deviation

*

unless otherwise specified